Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

2003 Vol. 21, No. 1

Cover
Display Method:
Clinical efficacy on chronic hepatitis B treated by lamivudine combination with oxymatrine
GU Jing-jing, Tian Gui-zhen
2003, (1): 3-4.
Abstract(2263) PDF (561KB)(943)
Abstract:
OBJECTIVE To study the efficacy and safety of lamivudine combination with oxymatrine in treating chronic hepatitis B.METHODS 67 patients were randomly divided into 2 groups.36 patients as a treatment group received 100mg·d-1,po,lamivudine combination with 600mg·d-1,im oxymatrine for 3 months.31 patients as a control group was treated only with routine therapy.RESULTS After completion of therapy,the change of liver function and mark of HBVM were observed.In the two groups,the recovery rate of ALT was 90.2% and 75.3%,the negative rate of HBeAg was 33.4% and 16.1%.The efficacy of the treatment group was higher than that of control group.(P<0.05).Side effects had not been found.CONCLUSION lamivudine combination with oxymatrine can improve the liver function and inhibit HBV.
2003, (1): 5-5.
Abstract(2511) PDF (164KB)(1295)
Abstract:
2003, (1): 6-7.
Abstract(2610) PDF (715KB)(442)
Abstract:
2003, (1): 8-10.
Abstract(2262) PDF (563KB)(1361)
Abstract:
2003, (1): 10-11.
Abstract(2147) PDF (543KB)(602)
Abstract:
2003, (1): 11-13.
Abstract(2341) PDF (824KB)(381)
Abstract:
2003, (1): 13-13.
Abstract(2239) PDF (306KB)(526)
Abstract:
2003, (1): 14-15.
Abstract(2439) PDF (329KB)(393)
Abstract:
2003, (1): 16-17.
Abstract(2191) PDF (326KB)(434)
Abstract:
Preparation and stability observation of electron medicinal membrane of roxithromycin
WANG Xiao-bo, WANG Jing-guo, XI Rong-gang, ZHANG Zhi-ran
2003, (1): 18-20.
Abstract(2696) PDF (648KB)(795)
Abstract:
OBJECTIVE To prepare electron medicinal membrane of roxithromycin. To develop a method for assay about electron medicinal membrane of roxithromycin and observe its stabilities.METHODS The electron medicinal membrane of roxithromycin was prepared with the electrothermic equipment.The content of roxithromycin was determined by HPLC.The analytical column was YWG-C18 column.The mobile phase was a mixture of acetonitrile methanol 0.5% ammonium acetate(100:80:60), with the detection wavelength at 235 nm. The stabilities of electron medicinal membrane of roxithromycin was studied by determining the changes of roxithromycin contents by HPLC after subjected to high temperature and humidity test.RESULTS The dosage of membrane of roxithromycin is 75mg. Its difference degree of weight is below 10%.Precision and stability were fine. The linear correlation was observed from the concentrations of 0.3 to 1.7mg·ml-1(r=0.9998). The average recovery was 99.23%. Resolution between roxithromycin and other peaks met the requirements. Thermal stabilities of electron medicinal membrane of roxithromycin is good. So is its moist stabilitie. CONCLUSIONS: Stabilities of electron medicinal membrane of roxithromycin is good.The method was convenient, selective and reproducible for assay about electron medicinal membrane of roxithromycin.
Evaluation of the correlation between in vitro release and in vitro absorption characteristics of nefopam sustained release capsules
YANG Hong-tu, CHANG Cui, NING De-e, XU Qun-ying, BI Dian-zhou
2003, (1): 20-23.
Abstract:
OBJECTIVE To evaluate the correlativity between in vitro release and in vivo absorption of nefopam sustained release capsules.METHODS The nefopam concentration in human plasma was determined by a high performance liquid chromatography method.According to the Wagner-Nelson formula,the percentage of in vivo absorption of two nefopam sustained release capsules were calculated.In vitro release of nefopam in 3 mediums of different pH was tested and the accumulated release percentage was calculated.RESULTS The variation of pH of mediums were no significant affect on in vitro release rate of nefopam.CONCLUSION A good correlativity was showed between in vivo absorption and in vitro release of nefopam sustained release capsules.
2003, (1): 23-24.
Abstract(1989) PDF (710KB)(757)
Abstract:
2003, (1): 24-27.
Abstract:
2003, (1): 27-27,40.
Abstract(1781) PDF (512KB)(729)
Abstract:
2003, (1): 28-31.
Abstract(10334) PDF (546KB)(5292)
Abstract:
2003, (1): 32-35.
Abstract(2841) PDF (736KB)(2373)
Abstract:
2003, (1): 36-37.
Abstract(1976) PDF (477KB)(766)
Abstract:
2003, (1): 37-39.
Abstract:
2003, (1): 39-40.
Abstract(2678) PDF (508KB)(617)
Abstract:
2003, (1): 41-42.
Abstract(2556) PDF (549KB)(567)
Abstract:
2003, (1): 42-42.
Abstract(2212) PDF (250KB)(460)
Abstract:
2003, (1): 43-44.
Abstract(2941) PDF (310KB)(1041)
Abstract:
2003, (1): 45-46.
Abstract(2004) PDF (233KB)(511)
Abstract:
2003, (1): 47-48.
Abstract(1784) PDF (302KB)(536)
Abstract:
2003, (1): 48-49.
Abstract(2334) PDF (241KB)(616)
Abstract:
2003, (1): 49-51.
Abstract(2366) PDF (468KB)(421)
Abstract:
2003, (1): 51-52.
Abstract(2214) PDF (245KB)(437)
Abstract:
2003, (1): 52-52.
Abstract(2607) PDF (135KB)(550)
Abstract:
2003, (1): 53-55.
Abstract(2120) PDF (738KB)(2347)
Abstract:
2003, (1): 56-60.
Abstract(2393) PDF (596KB)(963)
Abstract: